Journals / Turkish Journal of Hematology / 2011 / Cilt: 28 - Sayı: 1

Non-Hodgkin lenfoma ve akut lenfoblastik lösemili çocuklarda hiperürisemi ve tümör lizis sendromu

Hyperuricemia and tumor lysis syndrome in children with non-Hodgkin’s lymphoma and acute lymphoblastic leukemia

Pages
52–59
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Management with allopurinol and hydration was effective in this group of patients with high tumor burden.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to examine the incidence, clinical characteristics, and outcome of hyper- uricemia and tumor lysis syndrome (TLS) in children with non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL).
📊
Key Findings & Data:Materials and Methods: This retrospective study included data from 327 patients (113 NHL and 214 ALL).
💡
Conclusion & Impact:Management with allopurinol and hydration was effective in this group of patients with high tumor burden.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to examine the incidence, clinical characteristics, and outcome of hyper- uricemia and tumor lysis syndrome (TLS) in children with non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL). Materials and Methods: This retrospective study included data from 327 patients (113 NHL and 214 ALL). Results: Hyperuricemia occurred in 26.5% and 12.6% of the patients with NHL and ALL, respec- tively. The corresponding figures for TLS were 15.9% and 0.47% (p=0.001). All hyperuricemic NHL patients had advanced disease and renal involvement was present in 53%. All hyperuricemic ALL patients had a leukocyte count >50,000 mm3 at the time of diagnosis. Among the hyperuricemic NHL and ALL patients, 96.6% and 66.6% had LDH ≥500 UI/L, respectively. Treatment consisted of hydra- tion and allopurinol; none of the patients received urate oxidase. Among the patients that developed TLS, 26.3% had laboratory TLS, 42.1% had grade I or II TLS, and 31.6% had grade III or IV TLS. Uric acid levels returned to normal after a mean period of 3.5±2.5 and 3.05±0.8 d in NHL and ALL groups, respectively. In all, 7% of the patients with hyperuricemia required hemodialysis. None of the patients died. Conclusion: In this series the factors associated with a high-risk for TLS were renal involvement in NHL and high leucocyte count in ALL. Management with allopurinol and hydration was effective in this group of patients with high tumor burden.

Özet

Amaç: Çalışmanın amacı NHL ve ALL’li çocuklarda hiperürisemi ve TLS sıklığını, klinik özellikleri ve sonuçlarını tanımlamaktır. Yöntem ve Gereçler: Bu retrospektif çalışmada 113 NHL ve 214 ALL’li toplam 327 hastanın verileri değerlendirildi. Bulgular: NHL olgularının %26.5’inde, ALL olgularının %12.6’sında hiperürisemi görüldü. TLS insi- dansı NHL ve ALL gruplarında %15.9 ve %0.47 bulundu (p=0.001). Hiperürisemi görülen NHL olgularının tümü ileri evrede olup, %53’ünde renal tutulum vardı. Tüm hiperürisemili ALL olguların- da tanıda lökosit sayımı 50.000/mm3’den yüksekti. Hiperürisemik NHL grubunun %96.6’sında, ALL grubunun %66.6’sında LDH ≥500 UI/L idi. Tedavide hidrasyon ve allopürinol uygulandı, ürat oksidaz verilen hasta olmadı. TLS gelişen olguların %26.3’ünde laboratuvar TLS, %42,1’inde grade I ve grade II TLS, %31.6’sında grade III ve IV TLS saptandı. Ürik asit düzeyleri NHL ve ALL hastalarında orta- lama 3.5±2.5 ve 3.05±0.8 günde normale döndü. Hiperürisemili hastaların %7’sinde hemodiyaliz gerekti. Mortalite olmadı. Sonuç: Bu seride en yüksek TLS riski renal tutulumu olan NHL olgularında saptandı. Allopürinol ve hidrasyonun tümör yükü yüksek olan bu grupta etkili olduğu gözlendi.

🔖

Cite This Article

SEVİNİR, B. B., DEMİRKAYA, M., BAYTAN, B., GÜNEŞ, A. M. (2011). Non-Hodgkin lenfoma ve akut lenfoblastik lösemili çocuklarda hiperürisemi ve tümör lizis sendromu. Turkish Journal of Hematology, Cilt: 28 - Sayı: 1, 52–59. https://ajindex.com/articles/412899

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Davidson MB, Thakkar S, Hix JK, Bhandankar ND, Wong A, Schreiber MJ. Pathophysiology, clinical conse- quences, and treatment of tumor lysis syndrome. Am J Med 2004; 116:546-54. [CrossRef] Hochberg J, Cairo MS. Tumor lysis syndrome: Current perspective. Haematologica 2008; 93:9-13. [CrossRef] Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors- a case report and review of the litera- ture. Cancer Chemother Pharmacol 2003;51:187-92. Buyukpamukcu M. Non-Hodgkin’s lymphomas. In: Voute T, Kalifa C, Barret A (Eds). Cancer in children. Fourth edition, Oxford, UK: Oxford University Press; 1998;119-36.
  2. Kutluk T, Yesilipek MA. Turkish National Pediatric Cancer Registry 2002-2008 (Turkish Pediatric Oncology Group and Turkish Pediatric Hematology Society) Pediatr Blood Cancer 2009; 53:(abstract) pp25. Yaris N, Mandiracioglu A, Buyukpamukcu M. Childhood cancer in developing countries. Pediatr Hematol Oncol 2004;21:237-53. [CrossRef] Cairo M, Bishop M. Tumour lysis syndrome: new thera- peutic strategies and classification. Br J Haematol 2004;127:3-11. [CrossRef] Duzova A, Cetin M, Gümrük F, Yetgin S. Acute tumour lysis syndrome following a single-dose corticosteroid in children with acute lymphoblastic leukemia. Eur J Haematol 2001;66:404-7. [CrossRef] Eldar AH, Futerman B, Abrahami G, Attias D, Barak AB, Burstein Y, Dvir R, Gabriel H, Horovitz J, Kapelushnik J, Kaplinsky H, Miskin H, Sthoeger D, Toren A, Vilk-Revel S, Weintraub M, Yaniv I, Linn S, Arush MB. Burkitt lym- phoma in children. The Israeli Experience. J Pediatr Hematol Oncol 2009;31:428-36. [CrossRef] Seidemann K, Meyer U, Jansen P Yakisan E, Rieske K, Fuhrer M, Kremens B, Schrappe M, Reiter A. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin’s lymphoma and B-ALL. Observations from the BFM-trials. Klin Padiatr 1998;210:279-84. [CrossRef] Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.Ann Hematol 2003;82:160-5. [CrossRef] Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence -based review. J Clin Oncol 2008;26:2767-78. [CrossRef] Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, Babin-Boilletot A. Urate-oxidase in the prevention and treatment of metabolic complica- tions in patient